8-K: 10x Genomics Reports 20% Revenue Growth for Full Year 2023, Announces 2024 Outlook

10x Genomics announced a 20% revenue increase for 2023 and provided a 2024 revenue growth outlook of 8% to 12%.

Summary

• 10x Genomics reported a revenue of $184.0 million for the fourth quarter of 2023, an 18% increase compared to the same period in 2022.
• Full year 2023 revenue reached $618.7 million, a 20% increase from $516.4 million in 2022.
• The company's gross margin for Q4 2023 was 63%, down from 76% in the prior year, primarily due to a higher mix of spatial instrument sales.
• Operating expenses for Q4 2023 were $171.0 million, a 20% increase year-over-year, including $19.6 million in in-process R&D expenses.
• The operating loss for Q4 2023 was $55.2 million, compared to a $23.1 million loss in the same period of 2022.
• Net loss for Q4 2023 was $49.0 million, compared to a net loss of $17.2 million in Q4 2022.
• For the full year 2023, the operating loss was $265.3 million, compared to $167.9 million in 2022.
• The net loss for the full year 2023 was $255.1 million, compared to a net loss of $166.0 million in 2022.
• 10x Genomics had $388.7 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
• The company expects full year 2024 revenue to be between $670 million and $690 million, representing 8% to 12% growth.

Sentiment

Score: 5

Explanation: The document presents mixed results with strong revenue growth offset by declining margins and increasing losses. The future outlook is positive but tempered by the need to improve profitability.

Positives

• The company experienced strong revenue growth of 18% in Q4 2023 and 20% for the full year 2023.
• Cumulative instrument sales reached 5,966, indicating strong market adoption.
• The launch of preorders for new products like Visium HD and Chromium GEM-X demonstrates continued innovation.
• The company has a strong cash position with $388.7 million in cash, cash equivalents, and marketable securities.

Negatives

• Gross margin decreased significantly in both Q4 and full year 2023 due to a shift in product mix towards spatial instruments.
• Operating expenses increased by 20% in both Q4 and full year 2023, impacting profitability.
• The company reported a larger operating loss and net loss in both Q4 and full year 2023 compared to 2022.
• The company's net loss per share increased to $(0.41) in Q4 2023 and $(2.18) for the full year 2023.

Risks

• The decrease in gross margin due to product mix could continue to impact profitability.
• Increased operating expenses, particularly in R&D, may put pressure on the company's financial performance.
• The company's ability to achieve its 2024 revenue guidance is subject to market conditions and customer adoption of new products.
• The company's net losses are increasing year over year.

Future Outlook

10x Genomics expects full year 2024 revenue to be in the range of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.

Management Comments

• Serge Saxonov, Co-founder and CEO, stated that their innovation engine has consistently delivered transformational technologies.
• He also mentioned that they are building on the launch of Xenium with new products in each of their three platforms.

Industry Context

The announcement reflects the ongoing growth and competition in the single-cell and spatial biology market, with 10x Genomics focusing on innovation and product expansion to maintain its leadership position. The company's focus on new product launches and technology advancements is consistent with the industry's trend towards higher resolution and more comprehensive analysis tools.

Comparison to Industry Standards

• Competitors like Bio-Rad and Illumina also offer single-cell and spatial analysis solutions, but 10x Genomics is considered a leader in the field.
• The 20% revenue growth for 2023 is strong, but the decrease in gross margin is a concern compared to industry benchmarks.
• The company's operating losses are significant and need to be addressed to achieve profitability, which is a common challenge for growth-stage biotech companies.
• The launch of new products like Visium HD and Chromium GEM-X is crucial for maintaining a competitive edge against other companies in the market.

Stakeholder Impact

• Shareholders may be concerned about the increased losses and decreased gross margins.
• Employees may be impacted by the company's focus on cost management.
• Customers will benefit from the new product launches and technological advancements.
• Suppliers may see increased demand for components used in the company's products.

Next Steps

• The company will host a conference call to discuss the financial results and outlook.
• The company will focus on ensuring customer success with new product launches.
• The company will continue to develop and launch new products in its three platforms.

Key Dates

Keywords

10x Genomics, single cell biology, spatial biology, genomics, financial results, revenue growth, gross margin, operating expenses, net loss, instrument sales, Chromium, Visium, Xenium, GEM-X, 2024 outlook